Publications by authors named "S B Goldberger"
Emotions are powerful tools through which formal leaders influence their followers, whether by overt emotional displays or deliberate attempts to regulate their own and others' emotions. This raises the following question: Can the strategic effort to regulate others' emotions help team members emerge as informal leaders? This work demonstrates that extrinsic emotion regulation-a goal-directed action aimed at regulating team members' emotions-can enable individuals to rise to informal leadership positions. We hypothesize that team members who improve group emotions emerge as informal leaders.
View Article and Find Full Text PDFObjective: Enhancing cancer patients' sense of control can positively impact psychological well-being. We developed and assessed the psychometric properties of Valued Outcomes in the Cancer Experience (VOICE), a measure of patients' perceived control over key personal priorities within their cancer experience.
Methods: VOICE construction and testing were completed in three phases with separate participant samples: (1) item generation and initial item pool testing ( = 459), (2) scale refinement ( = 623), and (3) confirmatory validation ( = 515).
Purpose: The treatment of oligodendroglioma consists of tumor resection and radiochemotherapy. The timing of radiochemotherapy remains unclear, and predictive biomarkers are limited.
Experimental Design: Adult patients diagnosed with isocitrate dehydrogenase (IDH)-mutated, 1p/19q-codeleted CNS WHO grade 2 and 3 oligodendroglioma at the Medical University of Vienna and the Kepler University Hospital Linz (Austria) in 1992 to 2019 were included.
Article Synopsis
- Oral cavity squamous cell carcinoma (OCSCC) is challenging to treat, often leading to toxic side effects from conventional chemotherapy like platinum-based drugs.
- PRV111 is a new nanotechnology that allows for localized delivery of cisplatin to tumors, minimizing systemic exposure and toxicity while enhancing drug retention in the tumor.
- In animal studies and a clinical trial, PRV111 showed significant effectiveness with a 69% reduction in tumor size in about a week, no serious side effects, and suggests potential for better patient outcomes when combined with existing treatments for OCSCC.